JAK1 also has associated small molecule inhibitors which are tyrosine-protein kinase JAK1 inhibitors including abrocitinib, baricitinib and ruxolitinib, but have been primarily used in trials to treat autoimmune diseases such as atopic eczema, myelofibrosis and rheumatoid arthritis (Supplementary Tables S15 and S16). This evidence concerns the gene JAK1 and autoimmune disease.